85 results about "IMMUNE SUPPRESSANTS" patented technology

The invention discloses application of a metal boride nano material in preparation of an immunosuppressant, and belongs to the technical field of biological medicine. Specifically, through a series of researches, it is found that the metal boride nano material catalyzes an organic substrate containing a-CH-OH group in cells, and meanwhile, NAD (P) < + > is converted to generate NAD (P) H, GSH rising is promoted, and cell reductive stress is initiated. The immune cells are further induced to differentiate to an immunosuppressive phenotype, secretion of immunosuppressive factors is promoted, secretion of immune activating factors is inhibited at the same time, and finally the immunosuppressive effect is achieved. The catalytic action of the substance can provide a lasting and stable immunosuppression effect, and the feasibility of the substance in initiation of reduction stress and immunosuppression is proved through in-vivo and in-vitro experiments. The invention provides a new immunosuppression strategy, which is expected to make up the defects of the traditional immunosuppressor, and provides a new choice for related treatment of clinical organ transplantation, autoimmune diseases, inflammatory diseases and the like.

The invention discloses a thiadiazolidinone compound and a preparation method and application thereof, the thiadiazolidinone derivative is a compound with a structure shown as a general formula (I) or pharmaceutically acceptable salt of the compound, and the invention further discloses application of the thiadiazolidinone derivative in medicine for treating PTPN2 / PTPN1 mediated diseases. The compound disclosed by the invention has obvious inhibitory activity on PTPN2 / PTPN1 phosphatase, has important influence on occurrence and development of tumors and immune response, can also be used in combination with an immunosuppressant to treat related immune diseases, can be developed into an anti-tumor drug with high activity, good selectivity and small toxic and side effects, and has the characteristics of strong plasticity and great future modification potential. # imgabs0 #

To provide methods that offer immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules.SOLUTION: A method comprises: administering an immunosuppressant to a subject at an administration dose that provides an administration pharmacodynamic effective-life, with respect to a therapeutic macromolecule, the duration of which pharmacodynamic effective-life ranges from a minimum of 20 hours to a maximum of 1 month; and administering the therapeutic macromolecule to the subject within the duration of the administration pharmacodynamic effective-life of the immunosuppressant; wherein the therapeutic macromolecule and immunosuppressant are not attached to one another, and the therapeutic macromolecule is not attached to a synthetic nanocarrier. The method allows shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.SELECTED DRAWING: Figure 1

The present invention relates to combination therapy compositions and methods of combination therapy for the treatment of cancer. The present invention discloses a composition comprising: (i) an effective amount of a programmed cell death protein-1 (PD-1) inhibitor capable of blocking a PD-1 pathway, partially recovering the function of T cells, and enabling these cells to continue killing tumor cells; and (ii) an effective amount of a glucosylceramide synthetase (GCS) inhibitor capable of enhancing the activity of the immune system; wherein the immunosuppressive agent is administered intravenously by using an intravenous dosage form, and the GCS inhibitor is administered orally by using an oral dosage form. The tumor growth can be effectively inhibited by using the composition and the combined treatment method disclosed by the invention.

The present application relates to the technical field of medicine, and specifically includes the application of immunosuppressants in the preparation of drugs for treating pulmonary hypoperfusion type congenital heart disease, and further provides a premature infant pulmonary hypoperfusion animal model, and results show that lung development is significantly improved after using immunosuppressants. The present application verifies the Wnt pathway which is critical for lung development, indicates that immunosuppressants can improve the Wnt pathway changes caused by pulmonary hypoperfusion, confirms that immunosuppressants have a therapeutic effect on the pulmonary hypoperfusion type congenital heart disease caused by pulmonary hypoplasia, provides a new method and idea for improving lung development of such children, and thereby improves the long-term survival quality of congenital heart disease children in China.

This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and / or variants thereof for use in CRISPR-based gene editing.

The invention belongs to the field of medicine preparation, and particularly relates to bispecific cell membrane nanoparticles and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out in-vitro induction on primary CD4 + T cells by adopting TGF-beta and rapamycin to obtain regulatory T cells; enabling the distearoyl phosphatidyl ethanolamine-polyethylene glycol-active ester to react with the anti-CD4 antigen binding fragment, so as to obtain DP-aCD4; pre-incubating free aCD4 by the regulatory T cell, and co-incubating with DP-aCD4 to obtain an aCD4-regulatory T cell; the aCD4-regulatory T cells are mixed with an antigen peptide and an immunosuppressive agent, and the bispecific cell membrane nanoparticles AP-IA (at) aCD4Tn are prepared through a liposome extruder. After in-vivo administration of the bispecific cell membrane nanoparticles, generation of antigen-specific regulatory T cells can be efficiently induced, and accurate and efficient treatment and prevention of rheumatoid arthritis are realized.

The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonary chronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.

Provided is a means for quantitative analysis of an analyte including mycophenolic acid and one or more other immunosuppressants using a whole blood fraction without requiring separation of a blood sample. One embodiment of the present invention relates to a method for quantifying an analyte including mycophenolic acid and one or more other immunosuppressants in a blood sample of a subject, the method comprising: an analyte concentration measurement step for measuring the concentration of the analyte; measuring the concentration of an analyte including mycophenolic acid and one or more other immunosuppressants in the whole blood fraction of the blood sample; a hematocrit value acquisition step for acquiring the hematocrit value of the target blood sample; and a mycophenolic acid concentration conversion step for converting the concentration of mycophenolic acid in the whole blood fraction of the blood sample into the concentration of mycophenolic acid in the plasma fraction of the blood sample on the basis of the hematocrit value.

The present application relates to an organic compound having mTOR inhibitory activity, a preparation method therefor, a pharmaceutical composition comprising the organic compound, and a use thereof for the treatment or prevention of a disease responsive to mTOR inhibition. In particular, the compound of the present invention can be used in the treatment of a disease responsive to mTOR inhibition or a condition requiring mTOR inhibition, such as cancer, a nervous system disease, a metabolic disease, an autoimmune disease, or organ fibrosis, or can be used as an immunosuppressant.

Provided is a medicine for promoting induction of differentiation of oligodendrocyte progenitor cells into oligodendrocytes, and a medicine for promoting remyelination. The medicine contains a vitamin D derivative represented by formula (1) or a pharmaceutically acceptable salt or solvate thereof and used in combination with an immunosuppressant.

The invention discloses an immune tolerance realization method based on immune cell negative selection, which comprises the following steps: step 1, separating mononuclear cells from peripheral blood of a patient, and inducing and differentiating the mononuclear cells into DCs in vitro; 2, introducing the Aire gene into DCs by using a virus vector adeno-associated virus (AAV) or a lentivirus; 3, over-expressing Aire protein by the modified DCs, so that the modified DCs can express a plurality of autoantigens; and step 4, injecting the DCs subjected to Aire overexpression back into the body of the patient, and inducing immune tolerance. The preparation method has the beneficial effects that the immune regulation function of DCs is enhanced through the Aire gene, the activity of autoreactive T cells is inhibited, and the damage to pancreatic beta cells is reduced; dependence on a traditional immunosuppressor is reduced, and side effects are reduced; a novel treatment method is provided for autoimmune diseases such as type 1 diabetes, and high safety and specificity are achieved.

Provided is an immunomodulatory treatment composition for a transplantation disease through combined administration of a microbiome and an immunosuppressant. According to the present disclosure, it was confirmed that in an allogeneic transplantation cell model, combined administration of FK506 and the microbiome suppressed alloresponse and regulated the activity of T cells and B cells. Further, it was confirmed that in an acute graft-versus-host disease animal model, the combined administration reduced the disease activity, increased the probability of survival, and protected the tissue damage. In addition, it was confirmed that the combined administration improved transplantation rejection diseases by reducing the activity of Th1 and Th17 and increasing the activity of Tregs, and thus can be usefully used as an immunomodulator for transplantation rejection.

An immunosuppressant having the structure of formula (I), and a preparation method therefor and the use thereof are provided. The series of compounds can be widely used in the preparation of drugs for preventing and / or treating cancers or tumors, immune-related diseases and disorders, communicable diseases, infectious diseases or metabolic diseases mediated by PD-1 / PD-L1 signal pathways, which drugs are expected to be developed into a new generation of PD-1 / PD-L1 inhibitors.

Systems and methods are provided that assess eye movement in multiple sclerosis (MS) patients receiving different drugs (e.g., dimethyl fumarate, fingolimod, clababine, ofarmumab) or treatments that (a) alleviate inflammation that may cause a symptom of multiple sclerosis and prevent nerve injury that may cause a symptom of multiple sclerosis); (b) testing sphingosine-1-phosphate receptor modulators that chelate lymphocytes in the lymphocyte nodes, preventing them from causing an autoimmune response); (c) checking for immunosuppressants acting on the lymphocyte pathway); and (d) analyzing the effect of the monoclonal antibody in inhibiting activation of lymphocyte B.

This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for detecting the presence of autoantibodies specific for an EXT1 and / or EXT2 polypeptide as well as methods and materials for detecting the presence of kidney tissue having an elevated level of an EXT1 and / or EXT2 polypeptide are provided. In addition, methods and materials for treating membranous nephropathy by administering an immunosuppressant are provided.

The application discloses application of pulegone as an effective component in an immunosuppressant, and the pulegone with significant calcineurin (CN) inhibiting activity is screened from the Schleichera oleosa Kurz, the immunosuppressive effect of the pulegone is equivalent to that of cyclosporine A which is widely used in clinic, mechanism research shows that the pulegone targets CN / NFAT signal path to play the immunosuppressive activity, and the pulegone has very weak cytotoxicity to spleen cells, and is a high-efficiency and low-toxicity immunosuppressant.

This invention discloses an antimicrobial peptide for controlling the fall webworm. Hcattacin1 Gene dsRNA and its application in the control of the American white moth. Hcattacin1 The gene's nucleotide sequence is SEQ ID NO: 1. This invention is based on antimicrobial peptides. Hcattacin1 dsRNA was genetically engineered, and a method for controlling the fall webworm using injection was established. Hcattacin1 An RNA interference system was used, and it was found that injection into the fall webworm (American white moth) achieved a significant gene silencing effect. Furthermore, the fall webworm was used in conjunction with other RNA interference methods. Hcattacin1 The combined use of dsRNA and biocontrol bacteria can significantly improve the control efficacy of biocontrol bacteria. This invention lays the theoretical foundation for the development of immunosuppressants that are safe for humans and animals, provides a new theory for the biological control of pests, and ultimately offers new strategies and approaches for pest control in my country's green agricultural production and sustainable development.

The invention relates to an application of a soluble epoxide hydrolase inhibitor in the field of transplantation, the soluble epoxide hydrolase inhibitor is TPPU, and the soluble epoxide hydrolase inhibitor is applied in the fields of organ transplantation and tissue transplantation. The TPPU is used for relieving allogeneic mouse heart and skin transplantation immunological rejection, reducing immune cell infiltration in transplantation operation, and inhibiting CD4 + T cell proliferation, CXCR3 chemokine receptor positive and Th1 cell subset proportion. The TPPU inhibits proliferation of primary CD4 + T cells of normal mice and differentiation of Th1 cell subgroups. In organ transplantation and tissue transplantation, the invention provides a single soluble epoxide hydrolase inhibitor TPPU, which can relieve allogeneic mouse heart and skin transplantation immunological rejection, inhibit normal mouse primary CD4 + T cell proliferation and differentiation, and reduce toxic and side effects caused by the use of an immunosuppressant.

The present invention provides an anti-TIGIT immunosuppressant and use thereof. The immunosuppressant can bind to the extracellular region of human TIGIT, and can be used for treating diseases such as a cancer.

The invention relates to the field of traditional Chinese medicines, in particular to a preparation method and application of a nephritis medicine. According to the invention, the extract A (volatile oil), the extract B (ethanol extract) and the extract C (aqueous extract) are mixed according to a specific ratio (such as 4: 6 or 5: 5), so that a multi-component synergistic effect is exerted, and the anti-inflammatory, anti-oxidation and renal function protection effects are remarkably enhanced. Based on natural components of a traditional Chinese medicine compound and an optimized extraction process, side effects of common immunosuppressants or hormone drugs in western medicines are avoided, and safer treatment choices are provided.

The invention discloses a multifunctional intravascular stent for diabetics and a preparation method of the multifunctional intravascular stent, and relates to the technical field of cardiovascular interventional therapy instruments. The polycitrate is used as a carrier on the surface of the intravascular stent body to form the drug-loaded slow-release coating, and the drug-loaded slow-release coating has high antioxidant content, can provide oxidative stress attenuation continuously for a long time, provides a good microenvironment for cell tissue recovery, and promotes regeneration and repair of blood vessels. The biological immunosuppressor and the diabetes specific drug are loaded in the drug-loaded slow-release coating, the biological immunosuppressor is a drug having an excellent effect on common patients, the diabetes specific drug is a drug having a specific effect on diabetic patients, and the two drugs have a synergistic effect, so that the effect of treating diabetes is achieved; the coating on the surface of the intravascular stent has the effects of resisting inflammation, improving endothelial dysfunction and inhibiting proliferation and migration of smooth muscle cells aiming at diabetic patients so as to promote regeneration and repair of diseased blood vessels of the diabetic patients.

The invention discloses a targeted silencing black-winged termite antibacterial peptide Oftermicin1 dsRNA of the gene and its application in termite control. Among them, black-winged termite Oftermicin1 The nucleotide sequence of the gene is SEQ ID NO: 1. The present invention is based on antimicrobial peptides Oftermicin1 We designed dsRNA and established a feeding method for the black-winged termite Oftermicin1 RNA interference system, and concluded that feeding had a significant gene silencing effect in black-winged termites. Oftermicin1 RNAi technology application provides technical support. In addition, this patent uses the established black-winged termite Oftermicin1 The RNA interference system Oftermicin1 The combination of dsRNA and biocontrol bacteria can significantly improve the control effect of biocontrol bacteria. The present invention lays a theoretical foundation for the development of immunosuppressants that are safe for humans and animals, and provides a new theory for biological control of pests, ultimately providing new strategies and new ways of pest control for my country's green agricultural production and sustainable development.

This invention discloses an epigenetic drug targeting lncRNA-PSF interaction, its composition, and its application. First, this invention synthesizes an epigenetic drug targeting lncRNA-PSF interaction as shown in formula (I) or formula (II). Compared with existing technologies, the epigenetic drugs shown in formulas (I) and (II) can inhibit lncRNA-PSF interaction, alter the cell cycle by increasing the expression of p27 and p53 proteins, arrest cancer cells in the G2 / M phase, and thus exert an anti-cancer effect. When the epigenetic drugs shown in formulas (I) and (II) are used in combination with immunosuppressants, they can enhance the effect of immunosuppressants, increase antigen presentation by cancer cells, and reduce their immune escape, thus becoming a novel anti-cancer sensitization strategy.

The invention belongs to the technical field of medicine application and biological medicine, and particularly relates to application of an AKT inhibitor in preparation of a medicine for inducing pancreas islet transplantation immune tolerance. The invention discovers that the AKT inhibitor MK-2206 can effectively induce immune tolerance after pancreas islet transplantation for the first time, system experiments prove that a short-term intervention scheme adopting the AKT inhibitor MK-2206 can obviously promote long-term survival of pancreas islet transplantation, and the effect of the AKT inhibitor MK-2206 is superior to that of a traditional immunosuppressor. The method belongs to secondary development of medicines with known active ingredients, and provides a potential novel treatment strategy for clinical induction of transplantation immune tolerance.

The invention discloses a targeted silencing black-winged termite Gram-negative bacteria recognition protein GNBP3 The invention relates to a dsRNA of a gene and its application in termite control. Specifically, black-winged termite GNBP3 The nucleotide sequence of the gene is SEQ ID NO: 1. This patent is the first to use the technology of bacterial amplification of dsRNA to synthesize the black-winged termite GNBP3 dsRNA, a feeding method was established to test the black-winged termite GNBP3 RNA interference system, first discovered using black-winged termites alone GNBP3 dsRNA has a high lethality rate against termites. GNBP3 The combination of dsRNA and biocontrol bacteria can significantly improve the control effect of biocontrol bacteria. The present invention lays a theoretical foundation for the development of immunosuppressants that are safe for humans and animals, and provides a new theory for biological control of pests, ultimately providing new strategies and new ways of pest control for my country's green agricultural production and sustainable development.

The present invention relates, at least in part, to repeated lower doses of viral vectors administered in combination with synthetic nanocarriers attached to immunosuppressant drugs, and related compositions.

The invention provides a traditional Chinese medicine composition for treating children nephrotic syndrome. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 16 to 24 parts of astragalus membranaceus, 12 to 18 parts of radix rehmanniae recen, 7.2 to 10.8 parts of dogwood, 9.6 to 14.4 parts of Chinese yam, 16 to 24 parts of radix pseudostellariae, 7.2 to 10.8 parts of poria cocos, 4.8 to 7.2 parts of bighead atractylodes rhizome, 4.8 to 7.2 parts of rhizoma atractylodis, 9.6 to 14.4 parts of moutan bark, 4 to 6 parts of pseudo-ginseng, 4.8 to 7.2 parts of divaricate saposhnikovia root and 12 to 18 parts of oldenlandia diffusa. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The medicine disclosed by the invention is used for treating children nephrotic syndrome, treating both symptoms and root causes, tonifying kidney without nourishing greasy feeling, inducing diuresis without hurting yin, activating blood without bleeding, and dispersing blood stasis without hurting vital qi, and has the effects of tonifying spleen and promoting diuresis, tonifying kidney qi, nourishing and reinforcing kidney yin, and dispersing blood stasis and inducing diuresis; the serum albumin level of a child patient can be improved, the 24-hour urine protein quantification and the serum total cholesterol level can be reduced, the remission rate can be improved clinically, the recurrence rate can be reduced, and the adverse reactions of hormones and immunosuppressants can be reduced.